EP1714653A4 - Aqueous solution preparation containing camptothecins - Google Patents

Aqueous solution preparation containing camptothecins

Info

Publication number
EP1714653A4
EP1714653A4 EP05709954A EP05709954A EP1714653A4 EP 1714653 A4 EP1714653 A4 EP 1714653A4 EP 05709954 A EP05709954 A EP 05709954A EP 05709954 A EP05709954 A EP 05709954A EP 1714653 A4 EP1714653 A4 EP 1714653A4
Authority
EP
European Patent Office
Prior art keywords
aqueous solution
preparation containing
solution preparation
camptothecins
containing camptothecins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05709954A
Other languages
German (de)
French (fr)
Other versions
EP1714653A1 (en
EP1714653B1 (en
Inventor
Masako Nakazawa
Ritsuo Aiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Publication of EP1714653A1 publication Critical patent/EP1714653A1/en
Publication of EP1714653A4 publication Critical patent/EP1714653A4/en
Application granted granted Critical
Publication of EP1714653B1 publication Critical patent/EP1714653B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

An aqueous solution preparation containing camptothecins which does not require heating in its production, and wherein camptothecins have been solubilized in a stable manner is provided. The aqueous solution preparation containing camptothecins contains acetic acid and sodium acetate, and it has a pH of 2 to 5.
EP05709954A 2004-02-13 2005-02-09 Aqueous solution preparation containing a camptothecin Not-in-force EP1714653B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004035985 2004-02-13
JP2004035986 2004-02-13
PCT/JP2005/001902 WO2005077370A1 (en) 2004-02-13 2005-02-09 Aqueous solution preparation containing camptothecins

Publications (3)

Publication Number Publication Date
EP1714653A1 EP1714653A1 (en) 2006-10-25
EP1714653A4 true EP1714653A4 (en) 2008-05-21
EP1714653B1 EP1714653B1 (en) 2010-11-24

Family

ID=34863456

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05709954A Not-in-force EP1714653B1 (en) 2004-02-13 2005-02-09 Aqueous solution preparation containing a camptothecin

Country Status (8)

Country Link
US (1) US20080242691A1 (en)
EP (1) EP1714653B1 (en)
JP (1) JP4451850B2 (en)
AT (1) ATE489094T1 (en)
CA (1) CA2556254A1 (en)
DE (1) DE602005024923D1 (en)
TW (1) TW200538457A (en)
WO (1) WO2005077370A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148080A2 (en) * 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
AU2009234283B2 (en) * 2008-04-11 2015-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diterpene glycosides as natural solubilizers
US8551507B2 (en) 2009-06-24 2013-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Terpene glycosides and their combinations as solubilizing agents
US10098813B2 (en) 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674874A (en) * 1993-12-22 1997-10-07 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl 10-hydroxy camptothecin and methods for uses thereof
US6476043B1 (en) * 1998-08-05 2002-11-05 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2003086471A2 (en) * 2002-04-16 2003-10-23 Tanabe Seiyaku Co., Ltd. Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (en) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd Novel camptothecin derivative
JP4094710B2 (en) * 1997-11-06 2008-06-04 株式会社ヤクルト本社 New camptothecin derivatives
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE60143857D1 (en) * 2000-03-09 2011-02-24 Univ Yale COMPOSITION COMPRISING PHY906 AND CHEMOTHERAPEUTICS
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
JP4245384B2 (en) 2003-03-18 2009-03-25 株式会社ヤクルト本社 Pharmaceutical composition containing camptothecins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674874A (en) * 1993-12-22 1997-10-07 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl 10-hydroxy camptothecin and methods for uses thereof
US6476043B1 (en) * 1998-08-05 2002-11-05 Aventis Pharma S.A. Use of camptothecin derivatives, with reduced gastrointestinal toxicity
WO2003086471A2 (en) * 2002-04-16 2003-10-23 Tanabe Seiyaku Co., Ltd. Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Also Published As

Publication number Publication date
ATE489094T1 (en) 2010-12-15
EP1714653A1 (en) 2006-10-25
JPWO2005077370A1 (en) 2007-10-18
TW200538457A (en) 2005-12-01
EP1714653B1 (en) 2010-11-24
DE602005024923D1 (en) 2011-01-05
WO2005077370A8 (en) 2006-01-05
JP4451850B2 (en) 2010-04-14
WO2005077370A1 (en) 2005-08-25
CA2556254A1 (en) 2005-08-25
US20080242691A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
AU2001236685A1 (en) Preparation of aqueous clear solution dosage forms with bile acids
WO2002005782A3 (en) Stable salts of o-acetylsalicyclic with basic amino acids
WO2002043580A3 (en) Production of microspheres
AU3668501A (en) Preparation of aqueous clear solution dosage forms with bile acids
WO2007005633A3 (en) Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
EP1679071A4 (en) Collagen productin enhancer and production process and use thereof
DE60120189D1 (en) PREPARATION OF CONCENTRATED BIOZID SOLUTIONS
HK1107922A1 (en) Suture with adhesive/sealant delivery mechanism
DE602006017057D1 (en) DEHYDRACETIC ACID COMPOSITIONS WITH LOW PH
CY1108593T1 (en) CONCENTRATED AQUATIC AMPROXOL SOLUTION
EP1582514A4 (en) Processes for producing glutamic acid derivative and pyroglutamic acid derivative and novel intermediate for production
WO2004083369A3 (en) Tissue binding composition
MY130441A (en) Solutions containing epinastin
EP1714653A4 (en) Aqueous solution preparation containing camptothecins
MXPA04007068A (en) Starch derivatives, starch active substance conjugates, method for the production thereof and their use as medicaments.
MXPA03011480A (en) Aqueous cilostazol preparation for injection.
WO2003078430A8 (en) Amides of acetic and propionic acids
WO2001093910A3 (en) Method for increasing the antioxidative potential of selenium-containing aqueous solutions
WO2003094905A8 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
WO2004085387A3 (en) Water-soluble mono-pegylated tetrapyrrole derivatives for photodynamic therapy and method of production
BR0010150A (en) Oral solution of prucalopride
AU2002218164A1 (en) Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
TW200727900A (en) Aqueous solution preparation containing camptothecins
WO2008053206A3 (en) Process for preparation of aldonic acids and derivatives thereof
MXPA04002640A (en) 3-desoxy-vitamin d3 analog esters.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060713

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080418

17Q First examination report despatched

Effective date: 20090219

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: AQUEOUS SOLUTION PREPARATION CONTAINING A CAMPTOTHECIN

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005024923

Country of ref document: DE

Date of ref document: 20110105

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20110302

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20101124

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110324

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110324

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110224

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20110301

Year of fee payment: 7

Ref country code: DE

Payment date: 20110223

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20110221

Year of fee payment: 7

Ref country code: GB

Payment date: 20110221

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110228

26N No opposition filed

Effective date: 20110825

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005024923

Country of ref document: DE

Effective date: 20110825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110209

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120209

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20121031

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005024923

Country of ref document: DE

Effective date: 20120901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120209

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20130708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101124